Christine Dufès
Cited by
Cited by
Dendrimers in gene delivery
C Dufès, IF Uchegbu, AG Schätzlein
Advanced drug delivery reviews 57 (15), 2177-2202, 2005
Preferential liver gene expression with polypropylenimine dendrimers
AG Schatzlein, BH Zinselmeyer, A Elouzi, C Dufes, YTA Chim, CJ Roberts, ...
Journal of Controlled Release 101 (1-3), 247-258, 2005
Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude
X Qu, VV Khutoryanskiy, A Stewart, S Rahman, ...
Biomacromolecules 7 (12), 3452-3459, 2006
Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors
C Dufes, WN Keith, A Bilsland, I Proutski, IF Uchegbu, AG Schätzlein
Cancer research 65 (18), 8079-8084, 2005
On the issue of transparency and reproducibility in nanomedicine
HS Leong, KS Butler, CJ Brinker, M Azzawi, S Conlan, C Dufès, A Owen, ...
Nature nanotechnology 14 (7), 629-635, 2019
Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles
C Dufes, JM Muller, W Couet, JC Olivier, IF Uchegbu, AG Schätzlein
Pharmaceutical research 21, 101-107, 2004
Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats
C Dufes, JC Olivier, F Gaillard, A Gaillard, W Couet, JM Muller
International journal of pharmaceutics 255 (1-2), 87-97, 2003
Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting
C Dufes, AG Schätzlein, L Tetley, AI Gray, DG Watson, JC Olivier, ...
Pharmaceutical research 17, 1250-1258, 2000
Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain
C Dufes, F Gaillard, IF Uchegbu, AG Schätzlein, JC Olivier, JM Muller
International journal of pharmaceutics 285 (1-2), 77-85, 2004
Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA
S Koppu, YJ Oh, RA Edrada-Ebel, DR Blatchford, L Tetley, RJ Tate, ...
Journal of Controlled Release 143 (2), 215-221, 2010
A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo
HS Bell, C Dufes, J O’Prey, D Crighton, D Bergamaschi, X Lu, ...
The Journal of clinical investigation 117 (4), 1008-1018, 2007
Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells
C Dufès, M Al Robaian, S Somani
Therapeutic delivery 4 (5), 629-640, 2013
Transferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain
S Somani, DR Blatchford, O Millington, ML Stevenson, C Dufès
Journal of Controlled Release 188, 78-86, 2014
Beyond delivery
C Dufes
Gene therapy 13, 739-740, 2006
Bioactive Polymers
I Uchegbu, AG Schatzlein, C Dufes
US Patent App. 11/577,339, 2008
Applications of dendrimers for brain delivery and cancer therapy
S Somani, C Dufès
Nanomedicine 9 (15), 2403-2414, 2014
PEGylation of polypropylenimine dendrimers: effects on cytotoxicity, DNA condensation, gene delivery and expression in cancer cells
S Somani, P Laskar, N Altwaijry, P Kewcharoenvong, C Irving, G Robb, ...
Scientific reports 8 (1), 9410, 2018
Liposomes encapsulating polymeric chitosan based vesicles—a vesicle in vesicle system for drug delivery
D McPhail, L Tetley, C Dufes, IF Uchegbu
International journal of pharmaceutics 200 (1), 73-86, 2000
Enhanced gene expression in tumors after intravenous administration of arginine-, lysine-and leucine-bearing polypropylenimine polyplex
H Aldawsari, RA Edrada-Ebel, DR Blatchford, RJ Tate, L Tetley, C Dufès
Biomaterials 32 (25), 5889-5899, 2011
Camptothecin-based dendrimersomes for gene delivery and redox-responsive drug delivery to cancer cells
P Laskar, S Somani, SJ Campbell, M Mullin, P Keating, RJ Tate, C Irving, ...
Nanoscale 11 (42), 20058-20071, 2019
The system can't perform the operation now. Try again later.
Articles 1–20